Clinical Outcomes by Sex after Pulsed Field Ablation of Atrial Fibrillation

Turagam, Mohit K.; Neuzil, Petr; Schmidt, Boris; Reichlin, Tobias; Neven, Kars; Metzner, Andreas; Hansen, Jim; Blaauw, Yuri; Maury, Philippe; Arentz, Thomas

Published in:
Jama cardiology

DOI:
10.1001/jamacardio.2023.3752

Publication date:
2023

JAMA Cardiology | Original Investigation

Clinical Outcomes by Sex After Pulsed Field Ablation of Atrial Fibrillation

Mohit K. Turagam, MD; Petr Neuzil, MD, PhD; Boris Schmidt, MD; Tobias Reichlin, MD; Kars Neven, MD, PhD; Andreas Metzner, MD; Jim Hansen, MD; Yuri Blaauw, MD; Philippe Maury, MD; Thomas Arentz, MD; Philipp Sommer, MD; Ante Anic, MD; Frederic Anselme, MD; Serge Boveda, MD, PhD; Tom Deneke, MD; Stephan Willems, MD; Pepijn van der Voort, MD; Roland Tilz, MD; Moritoshi Funasako, MD; Daniel Scherr, MD; Reza Wakili, MD; Daniel Steven, MD; Josef Kautzner, MD; Johan Vijgen, MD; Pierre Jais, MD; Jan Petru, MD; Julian Chun, MD; Laurent Roten, MD; Anna Füting, MD; Marc D. Lemoine, MD; Martin Ruwald, MD; Bart A. Mulder, MD; Anne Rollin, MD; Heiko Lehrmann, MD; Thomas Fink, MD; Zrinka Jurisic, MD; Corentin Chaumont, MD; Raquel Adelino, MD; Karin Nentwich, MD; Melanie Gunawardene, MD; Alexandre Ouss, MD; Christian-Hendrik Heeger, MD; Martin Manninger, MD, PhD; Jan-Eric Bohnen, MD; Arian Sultan, MD; Petr Peichl, MD; Pieter Koopman, MD; Nicolas Derval, MD; Thomas Kueffer, MSc; Vivek Y. Reddy, MD

IMPORTANCE Previous studies evaluating the association of patient sex with clinical outcomes using conventional thermal ablative modalities for atrial fibrillation (AF) such as radiofrequency or cryoablation are controversial due to mixed results. Pulsed field ablation (PFA) is a novel AF ablation energy modality that has demonstrated preferential myocardial tissue ablation with a unique safety profile.

OBJECTIVE To compare sex differences in patients undergoing PFA for AF in the Multinational Survey on the Methods, Efficacy, and Safety on the Postapproval Clinical Use of Pulsed Field Ablation (MANIFEST-PF) registry.

DESIGN, SETTING, AND PARTICIPANTS This was a retrospective cohort study of MANIFEST-PF registry data, which included consecutive patients undergoing postregulatory approval treatment with PFA to treat AF between March 2021 and May 2022 with a median follow-up of 1 year. MANIFEST-PF is a multinational, retrospectively analyzed, prospectively enrolled patient-level registry including 24 European centers. The study included all consecutive registry patients (age ≥18 years) who underwent first-ever PFA for paroxysmal or persistent AF.

EXPOSURE PFA was performed on patients with AF. All patients underwent pulmonary vein isolation and additional ablation, which was performed at the discretion of the operator.

MAIN OUTCOMES AND MEASURES The primary effectiveness outcome was freedom from clinically documented atrial arrhythmia for 30 seconds or longer after a 3-month blanking period. The primary safety outcome was the composite of acute (<7 days postprocedure) and chronic (>7 days) major adverse events (MAEs).

RESULTS Of 1568 patients (mean [SD] age, 64.5 [11.5] years; 1015 male [64.7%]) with AF who underwent PFA, female patients, as compared with male patients, were older (mean [SD] age, 68 [10] years vs 62 [12] years; $P < .001$), had more paroxysmal AF (70.2% [388 of 553] vs 62.4% [633 of 1015]; $P = .002$) but had fewer comorbidities such as coronary disease (9% [38 of 553] vs 15.9% [129 of 1015]; $P < .001$), heart failure (10.5% [58 of 553] vs 16.6% [168 of 1015]; $P = .001$), and sleep apnea (4.7% [18 of 553] vs 11.7% [84 of 1015]; $P < .001$). Pulmonary vein isolation was performed in 99.8% of female (552 of 553) and 98.9% of male (1004 of 1015; $P = .90$) patients. Additional ablation was performed in 22.4% of female (124 of 553) and 23.1% of male (235 of 1015; $P = .79$) patients. The 1-year Kaplan-Meier estimate for freedom from atrial arrhythmia was similar in male and female patients (79.0%; 95% CI, 76.3%-81.5% vs 76.3%; 95% CI, 72.5%-79.8%; $P = .28$). There was also no significant difference in acute major AEs between groups (male, 1.5% [16 of 1015] vs female, 2.5% [14 of 553]; $P = .19$).

CONCLUSION AND RELEVANCE Results of this cohort study suggest that after PFA for AF, there were no significant sex differences in clinical effectiveness or safety events.

Invited Commentary page 1151

Supplemental content

Author Affiliations: Author affiliations are listed at the end of this article.

Corresponding Author: Vivek Y. Reddy, MD, Helmsley Electrophysiology Center, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1030, New York, NY 10029 (vivek.reddy@mountsinai.org).

JAMA Cardiol. 2023;8(12):1142-1151. doi:10.1001/jamacardio.2023.3752
Published online November 1, 2023.

The role of sex in determining the risks and benefits of catheter ablation for atrial fibrillation (AF) is controversial because there are important differences in the incidence, presentation, and management of AF between male and female individuals.[1,2] Previous studies evaluating the association of sex with clinical outcomes using conventional AF thermal-ablative modalities such as radiofrequency or cryoablation are controversial due to mixed results.[2-13] Potential explanations for this disparity include the following: (1) a more complex clinical profile including older age in female individuals, (2) a greater number of comorbidities, (3) smaller left atria and thinner atrial walls, which can render the procedure to be more technically difficult, (4) longer AF duration due to delayed or less frequent referral for catheter ablation, (5) greater incidence of nonparoxysmal AF, (6) more extensive atrial fibrosis, and (7) a higher prevalence of non-pulmonary vein triggers in female individuals.[6,14-16]

Pulsed field ablation (PFA) is a novel, nonthermal cardiac ablation energy modality that, in preclinical studies, has demonstrated preferential myocardial tissue ablation by irreversible electroporation.[17-28] Importantly in clinical trials, PFA has demonstrated a unique safety profile, with no reported instances of pulmonary vein stenosis or evidence of esophageal injury.[29-34] Beyond the favorable safety profile, the first in-human PFA trials demonstrated an effectiveness ranging from 55% to 92% at 1 year depending on AF type, PFA technology used, and intensity of AF monitoring.[31,34-36]

Multinational Survey on the Methods, Efficacy, and Safety on the Postapproval Clinical Use of Pulsed Field Ablation (MANIFEST-PF) is a large patient-level registry that includes the first 24 centers that commenced the clinical use of PFA for the treatment of AF after regulatory approval in Europe. MANIFEST-PF includes the largest cohort of female patients treated with PFA and offers an important resource for assessing clinically important sex-based differences in response to PFA.

Key Points

Question Is patient sex associated with differences in clinical outcomes of pulsed field ablation (PFA) for the treatment of patients with atrial fibrillation (AF)?

Findings In this large cohort study using a patient-level registry including 1568 consecutive patients who underwent PFA for paroxysmal or persistent AF, there was no significant difference between male and female patients in the 1-year freedom from recurrent atrial arrhythmia or major adverse events.

Meaning Results suggest that there was no association between patient sex and clinical outcomes of PFA as similar outcomes were observed by sex at 1-year follow-up after PFA for treatment of AF.

Methods

Study Population

All patients in the MANIFEST-PF registry were included in this study. MANIFEST-PF was a retrospective analysis, conducted in accordance with the Declaration of Helsinki and approved by the Ethical Committee at Homolka Hospital. A waiver of consent was granted by the ethical committee due to the use of deidentified personal information. As previously described, MANIFEST-PF is a large multinational registry from 24 European centers, including patients (aged 18 years and older) who underwent first-ever PFA for paroxysmal AF, persistent AF, or long-standing persistent AF after regulatory approval in March 1, 2021, enrolling consecutive patients in approximately May 2022.[37] Patients were categorized by sex (male vs female) and evaluated for clinical outcomes of PFA within sex subgroups, including freedom from AF and adverse events. Participant race and ethnicity information was not collected as these data were not considered relevant to this analysis. Participating centers and additional author disclosures, respectively, are available in eAppendix 1 and 2 in Supplement 1. The results are reported based on Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guidelines.

Pulsed Field Ablation

Details of the treatment strategies and follow-up in the MANIFEST-PF registry have been previously described.[37] During PFA, a series of high-voltage, ultrashort electric pulses are delivered to the targeted area. These pulses create microscopic pores in the cell membranes of the cardiac tissue cells (electroporation), disrupting their function and leading to apoptosis. Among cell types, myocardial cells have the lowest thresholds to these electric fields, potentially permitting preferential myocardial ablation.

Briefly, patients underwent preablation transesophageal echocardiography or contrast-enhanced computed tomography, or intraprocedural intracardiac echocardiography (ICE), to rule out left atrial appendage thrombus. PFA was performed under moderate sedation or general anesthesia with endotracheal intubation. Electroanatomic mapping and ICE were performed at the operator's discretion. Ablation was performed by sequentially positioning the PFA catheter (Farawave [Boston Scientific Inc]) at each pulmonary vein (PV) ostium to deliver a series of applications in basket and flower orientations. Patients typically received PFA based on a standard protocol; 2 applications were delivered for each PV in a basket pose, then the basket was rotated approximately 36° to change the spline orientation, and another 2 applications were delivered. The same algorithm was repeated using the flower pose to extend the level of PV isolation (PVI). All patients underwent PVI, defined by entrance block as confirmed by the absence of electrograms. Isoproterenol or adenosine was administered at physician discretion. In patients with persistent AF and long-standing persistent AF, ancillary ablation included ablation of the posterior wall, roof, mitral isthmus, cavotricuspid isthmus, and other ablations were performed either with PFA or a commercially available radiofrequency ablation catheter at the operator's discretion. The treating physician made the decision about the use of antiarrhythmic drugs (AADs). Oral anticoagulation therapy was typically in accordance with current AF guidelines.

Scheduled patient follow-up was performed at 3, 6, and 12 months, with assessments for AF-associated symptoms, major or minor adverse events, and 12-lead ECGs or 24-hour Holter monitoring, as per physician discretion.

Primary and Secondary Clinical Outcomes

The primary effectiveness outcome in the MANIFEST-PF registry was freedom from documented atrial arrhythmia (AF, atrial flutter, or atrial tachycardia) outside the 90-day blanking period, lasting 30 seconds or longer irrespective of symptoms with or without AADs. The secondary effectiveness outcome was freedom from atrial arrhythmia outside the 90-day blanking period lasting 30 seconds or longer plus freedom from class I or III AADs or reablation.

The primary safety outcome included the composite of acute (<7 days postprocedure) and chronic (>7 days postprocedure) major adverse events. Major adverse events included atrioesophageal fistula, symptomatic pulmonary vein stenosis, cardiac tamponade/perforation requiring intervention or surgery, stroke or systemic thromboembolism, persistent phrenic nerve injury, vascular access complications requiring surgery, coronary artery spasm, and death. Minor adverse events included pericardial effusion without intervention, pericarditis, air embolism, transient ischemic attack (TIA), transient phrenic nerve injury, vascular complications not requiring surgery, deep vein thrombosis, and respiratory-related complications.

Statistical Analysis

Descriptive characteristics are reported as mean (SD) or median (IQR) values for continuous variables (based on normality distribution) and counts or percentages for categorical variables. Comparisons between groups were performed using *t* tests or the Mann-Whitney *U* test for continuous variables and Pearson χ^2 test or Fisher exact test for categorical variables. A propensity score–matched analysis was performed for those baseline characteristics that typically affect AF ablation outcomes: age, body mass index (BMI), coronary artery disease, heart failure, hypertension, sleep apnea, and diabetes. The primary and secondary effectiveness outcomes were estimated using the Kaplan-Meier method, and survival curves were compared using the log-rank test. Baseline characteristics were examined in the univariate analysis, with the primary effectiveness outcome of atrial arrhythmia recurrence as the dependent variable. Variables with $P < .10$ in the univariate analysis were included in a multivariate Cox model. Multiple imputations were performed to account for missing data. Cox proportional hazards models were used to identify factors associated with primary effectiveness failure, with an estimation of the hazard ratio (HR) and 95% CI. All tests were 2-tailed, and *P* values < .05 indicated statistical significance. All statistical analyses were performed using the SPSS software, version 29.0 (IBM Corp).

Table 1. Baseline Characteristics

Characteristics	No. (%) of patients with available data	Entire cohort (N = 1568)	Female patients (n = 553)	Male patients (n = 1015)	*P* value
Age, mean (SD), y	1568 (100)	64.5 (11.5)	68.2 (10.3)	62.5 (11.6)	<.001
AF type, No. (%)					
Paroxysmal	1568 (100)	1021 (65)	388 (70.2)	633 (62.4)	.002
Persistent	1568 (100)	498 (32)	150 (27.1)	348 (34.3)	.03
Long-standing persistent	1568 (100)	49 (3)	15 (2.7)	34 (3.3)	.50
CHA_2DS_2-VASc, mean (SD)	1568 (100)	2.2 (1.6)	3.0 (1.5)	1.8 (1.5)	<.001
Medical history					
Body mass index, mean (SD)	1554 (99.1)	28 (5)	27.7 (5.7)	28.2 (4.5)	.051
Atrial flutter, No. (%)	1235 (78.8)	158 (12.8)	43 (10.1)	115 (14.2)	.05
Coronary artery disease, No. (%)	1235 (78.3)	167 (13.5)	38 (9.0)	129 (15.9)	<.001
Diabetes, No. (%)	1568 (100)	196 (12.5)	71 (12.8)	125 (12.3)	.81
Hypertension, No. (%)	1568 (100)	959 (61.1)	348 (62.9)	611 (60.2)	.30
Heart failure, No. (%)	1568 (100)	226 (14.4)	58 (10.5)	168 (16.6)	.001
Sleep apnea, No. (%)	1104 (70.4)	102 (9.2)	18 (4.7)	84 (11.7)	<.001
Prior stroke/TIA, No. (%)	1568 (100)	97 (6.2)	34 (6.1)	63 (6.2)	>.99
COPD, No. (%)	992 (63.3)	50 (5)	18 (5.3)	32 (4.9)	.76
Echocardiographic parameters					
LVEF, median (IQR), %	1381 (88.1)	60 (55-64)	60 (55-65)	60 (54-63)	.01
LA diameter, median (IQR), mm	1220 (77.8)	42 (39-46)	42 (38-45)	42 (39-46)	<.001
Antiarrhythmic medications					
Class I AADs (%)	1566 (99.9)	343 (21.9)	129 (23.3)	214 (21.1)	.34
Class III AADs (%)	1567 (99.9)	279 (17.8)	95 (17.2)	184 (18.1)	.68

Abbreviations: AAD, antiarrhythmic drug; AF, atrial fibrillation; CHA_2DS_2-VASc, congestive heart failure, hypertension, age, diabetes mellitus, prior stroke or TIA or thromboembolism, vascular disease, age, sex category; COPD, chronic obstructive pulmonary disease; LA, left atrium; LVEF, left ventricular ejection fraction; TIA, transient ischemic attack.

Results

Baseline Characteristics

The MANIFEST-PF registry included 1568 patients (mean [SD] age, 64.5 [11.5] years; 1015 male [64.7%]; 553 female [35.3%]) with AF who underwent PFA (**Table 1**). On average, female patients as compared with male patients were older (mean [SD] age, 68 [10] years vs 62 [12] years; $P < .001$) and had more paroxysmal AF (70.2% [388 of 553] vs 62.4% [633 of 1015]; $P = .002$) but fewer comorbidities such as coronary disease (9% [38 of 553] vs 15.9% [129 of 1015]; $P < .001$), heart failure (10.5% [58 of 553] vs 16.6% [168 of 1015]; $P = .001$), and sleep apnea (4.7% [18 of 553] vs 11.7% [84 of 1015]; $P < .001$). In addition, female patients were less likely to have persistent AF than male patients (27.1% [150 of 553] vs 34.3% [348 of 1015]). The prevalence of hypertension, diabetes, chronic obstructive pulmonary disease, and previous stroke or TIA were similar between female and male individuals. There was no difference in the use of preablation class I and III AADs between groups. The baseline characteristics based on AF type between male and female individuals are shown in eTable 1 in Supplement 1.

Procedural Characteristics

A similar proportion of male and female individuals underwent PFA with endotracheal intubation, electroanatomic mapping, and ICE imaging (**Table 2**). PVI was successfully achieved in almost all patients (99.8% of female [552 of 553] and 98.9% of male [1004 of 1015]; $P = .90$). Additional ablation was performed in 22.4% of female (124 of 553) and 23.1% of male (235 of 1015; $P = .79$) patients. There were no significant differences in the use of adjunctive lesion sets between male and female individuals undergoing ablation for paroxysmal AF (15.2% [59 of 388] vs 12.1% [77 of 633]; $P = .22$) or persistent AF (39.3% [65 of 165] vs 41.3% [158 of 382]; $P = .77$). Female patients were more likely to undergo additional mitral isthmus ablation than male patients for persistent AF (7.9% [13 of 165] vs 3.1% [12 of 382]; $P = .02$) (eTable 2 in Supplement 1). The median (IQR) fluoroscopy (11 [6-17] minutes vs 14 [7-22] minutes; $P = .004$) and procedure times (60 [40-93] minutes vs 72 [48-103] minutes; $P = .002$) were shorter in female patients for persistent AF but not for paroxysmal AF ablation (eTable 2 in Supplement 1). The group of patients requiring a repeated ablation procedure constituted only a small subset of the full cohort (147 of 1568 patients [9.4%]). The likelihood of undergoing repeated ablation did not differ between the female and male patients (8.3% [46 of 553] vs 10.0% [101 of 1015]; $P = .32$).

Follow-Up

There was no significant difference in the median (IQR) number of follow-up visits (3 [2-3] visits vs 3 [2-3] visits; $P = .76$), 24-hour Holter monitoring (2 [1-3] vs 2 [1-3]; $P = .54$), and follow-up duration (367 [306-428] days vs 366 [279-420] days; $P = .40$) between the 2 groups (**Table 3**).

Primary and Secondary Effectiveness Outcomes

The primary effectiveness outcome of the 1-year Kaplan-Meier estimate for freedom from AF, atrial flutter, and atrial tachycardia after a single procedure was similar between groups (female: 76.3%; 95% CI, 72.5%-79.8% vs male: 79.0%; 95% CI, 76.3%-81.5%; $P = .28$). Compared with male patients, there was no significant difference in the median (IQR) time to the first AF recurrence in female patients (176 [126-253] days vs 183 [130-296] days; $P = .21$). Clinical effectiveness was higher for par-

Table 2. Procedural Characteristics

Procedure characteristics	No. (%)[a]				
	No. of patients with available data	Entire cohort (N = 1568)	Female patients (n = 553)	Male patients (n = 1015)	*P* value
Intubation	1568 (100)	317 (20)	108 (19.5)	209 (20.6)	.65
Mapping	1568 (100)	457 (29)	152 (27.5)	305 (30.1)	.29
ICE imaging	1234 (79)	407 (33)	145 (34.2)	262 (32.3)	.52
Ablation lesion sets					
Acute PV isolation	1568 (100)	1556 (99.2)	552 (99.8)	1004 (98.9)	.90
Additional non-PV ablation	1568 (100)	359 (22.8)	124 (22.4)	235 (23.1)	.79
Posterior wall ablation	1568 (100)	173 (11)	55 (10.0)	118 (11.6)	.36
Mitral line	1568 (100)	37 (2.4)	21 (3.8)	16 (1.6)	.008
CTI line	1568 (100)	84 (5.4)	24 (4.3)	60 (5.9)	.20
Roof line	1568 (100)	21 (1.3)	8 (1.4)	13 (1.3)	.82
Other ablation	1568 (100)	44 (2.8)	16 (2.9)	28 (2.8)	.87
Type of energy used to perform additional ablation					
Pulsed field energy	359 (100)	305 (85)	111 (20.1)	194 (19.1)	.71
Radiofrequency	359 (100)	54 (15)	13 (2.3)	41 (4.0)	.09
Fluoroscopy time, median (IQR), min	1521 (97.0)	12 (7-19)	11.0 (6.6-17.2)	12.0 (7.0-19.4)	.05
Procedure time, median (IQR), min	1540 (98.2)	61 (40-90)	57.0 (40.0-87.5)	65 (42.0-92.0)	.002
Same day discharge	1234 (78.7)	101 (6.4)	37 (8.7)	64 (7.9)	.66

Abbreviations: CTI, cavotricuspid isthmus; ICE, intraprocedural intracardiac echocardiography; PV, pulmonary vein.

[a] Values listed as No. (%) unless otherwise specified.

Table 3. Effectiveness Outcomes

Effectiveness outcomes	No. (%)[a] Entire cohort (N = 1568)	Female patients (n = 553)	Male patients (n = 1015)	*P* value
Primary effectiveness outcome				
Freedom from AF/AFL/AT	1224 (78.1)	422 (76.3)	802 (79.0)	.28
Secondary effectiveness outcome				
Freedom from AF/AFL/AT not taking AADs or repeated ablation	1110 (70.8)	376 (68.0)	734 (72.3)	.10
Follow-up duration, median (IQR), d	367 (289-421)	367 (306-428)	366 (279-420)	.40
No. of follow-up 24-h Holter monitors, median (IQR)	2 (1-3)	2 (1-3)	2 (1-3)	.54
No. of follow-up visits, median (IQR)	3 (2-3)	3 (2-3)	3 (2-3)	.76
Time to AF/AFL recurrence, median (IQR), d	180 (129-266)	183 (130-296)	176 (126-253)	.21
Repeated ablation	147 (9.3)	46 (8.3)	101 (10.0)	.32

Abbreviations: AAD, antiarrhythmic drug; AF, atrial fibrillation; AFL, atrial flutter; AT, atrial tachycardia.

[a] Values listed as No. (%) unless otherwise specified.

oxysmal AF (female: 80.2% [75.8%-84.0%] vs male: 82.5% [79.2%-85.3%]; *P* = .30) than for persistent AF/long-standing persistent AF (female: 67.3% [59.5%-74.3%] vs male: 73.3% [68.5%-77.7%]; *P* = .40) but similar in both sexes (**Figure**).

The secondary effectiveness outcome of the 1-year Kaplan-Meier estimate for freedom from atrial arrhythmias without AADs or repeated ablation was also similar between groups (female: 68.0%; 95% CI, 63.9%-71.9% vs male: 72.3%; 95% CI, 69.4%-75%; *P* = .10) (eFigure 1 in Supplement 1). However, secondary clinical effectiveness was higher in male compared with female individuals in patients with paroxysmal AF (75.7%; 95% CI, 79.2%-85.3% vs 70.9%; 95% CI, 75.8%-84.0%; *P* = .04) and similar in patients with persistent AF/long-standing persistent AF (66.8%; 95% CI, 61.8%-71.4% vs 61.2%; 95% CI, 53.3%-68.7%; *P* = .59) (eFigure 2 in Supplement 1).

Risk Factors Associated With Primary and Secondary Effectiveness Outcomes

Multivariable Cox regression modeling was performed to identify potential risk factors associated with primary and secondary effectiveness failure (eTables 3-6 in Supplement 1). Primary effectiveness failure was associated with persistent AF (HR, 1.34; 95% CI, 1.05-1.70; *P* = .02), left ventricular ejection fraction (LVEF; HR, 0.98; 95% CI, 0.97-1.00; *P* = .047), left atrium (LA) diameter (HR, 1.02; 95% CI, 1.01-1.03; *P* = .004), and procedure time (HR, 1.00; 95% CI, 1.00-1.01; *P* = .04) (eTable 5 in Supplement 1), whereas secondary effectiveness failure was associated with LVEF (HR, 0.98; 95% CI, 0.97-0.99; *P* = .004) and LA diameter (HR, 1.02; 95% CI, 1.01-1.03; *P* = .007) (eTable 6 in Supplement 1). Female sex was not a risk factor of failure of primary or secondary effectiveness. These clinical risk factors remained consistent in both paroxysmal and persistent AF cohorts.

In the 553 female patients in the MANIFEST-PF registry, the clinical variables that were associated with primary effectiveness failure were history of persistent AF (HR, 2.2; 95% CI, 1.21-3.97; *P* = .01) and LA diameter 45 mm or greater (HR, 2.23; 95% CI, 1.32-3.90; *P* = .003) (eFigure 3 in Supplement 1).

Safety Outcomes

The overall rate of adverse events was low, with major adverse events occurring in 2.5% of female (14 of 553) and 1.5% of male (16 of 1015; *P* = .19) (**Table 4**) patients. There have been no reports of PFA-associated symptomatic PV stenosis or esophageal complications, including atrioesophageal fistula, esophageal ulcerations, or esophageal dysmotility in either group. Transient phrenic nerve injury occurred in 0.2% of female (1 of 553) and 0.5% of male (5 of 1015; *P* = .67) patients, whereas persistent phrenic nerve injury occurred in 1 female (0.2%) and in no male patients. Coronary spasm (female, 0.2% [1 of 553]; male, 0.1% [1 of 1015]) and vascular access complications requiring surgery (female, 0.2% [1 of 553]; male, 0.1% [1 of 1015]) were rare in both sexes.

Complications associated with catheter manipulation, such as cardiac tamponade, occurred in 1.4% of female (8 of 553) and 1.0% of male (10 of 1015; *P* = .46) patients. Stroke rates were similar in both sexes, occurring in 0.4% of female patients (2 of 553), with 1 stroke resulting in death, and in 0.4% of male patients (4 of 1015; *P* > .99).

There was also no significant difference in the incidence of acute minor adverse events (female, 3.1% [17 of 553] vs male, 4.5% [46 of 1015]; *P* = .17) between groups. Most of these were vascular complications that were conservatively managed.

Outcomes From Repeated Ablation Procedures

Of the 344 patients with recurrence of atrial arrhythmia after the index PFA procedure, at least 1 repeated procedure was performed in 147 patients (42.7%). Of these patients, 8.3% (46 of 553) were female and 10.0% (101 of 1015) were male (*P* = .32). Among the patients who underwent repeat ablation, per-vein durability was similar between female and male individuals (82.6% [152 of 184] vs 68.1% [275 of 404], respectively; *P* = .15), but per-patient PVI durability was significantly higher in female than male individuals (63.0% [29 of 46] vs 37.8% [38 of 101], respectively; *P* = .005) (eFigure 4 in Supplement 1).

Propensity Score-Matched Population

The propensity-matched cohort included 730 patients (365 male, 365 female). The mean (SD) age was 66.5 (9.5) years, the mean (SD) BMI was 27.8 (4.9; calculated as weight in kilograms divided by height in meters squared), and the mean (SD) CHA_2DS_2-VASc score was 2.2 (1.6). The CHA_2DS_2-VASc score assesses risk in AF and stands for congestive heart failure, hypertension, age, diabetes, prior stroke or TIA or thromboem-

bolism, vascular disease, age, and sex category. After propensity matching for risk factors, including age, BMI, coronary artery disease, diabetes, hypertension, heart failure, and sleep apnea, female patients had a higher prevalence of paroxysmal AF (70.1% [256 of 365] vs 57.8% [211 of 365]; $P < .001$), whereas male patients had a higher prevalence of persistent AF (38.4% [140 of 365] vs 27.9% [102 of 365]; $P = .03$) and a larger median (IQR) LA diameter (43 [40-47] mm vs 42 [38-45] mm; $P < .001$). Other baseline characteristics were similar between sexes in the propensity-matched cohort (eTable 7 in Supplement 1).

In the propensity-matched cohorts, there was again no difference in AF recurrence between sexes for either paroxysmal or persistent AF (eFigures 5 and 6 in Supplement 1). A multivariate Cox regression analysis was performed including age, female sex, BMI, history of persistent AF, diabetes, hypertension, heart failure, sleep apnea, CHA_2DS_2-VASc score, LVEF, LA diameter, PVI plus ablation, and procedure time. Persistent AF (HR, 2.1; 95% CI, 1.37-3.22; $P < .001$) and LA diameter (HR, 1.04; 95% CI, 1.02-1.06; $P < .001$) were associated with primary effectiveness failure (eTable 8 in Supplement 1).

Discussion

MANIFEST-PF is a large registry including 1568 patients with AF who underwent first-time catheter ablation using pulsed field energy in both male and female individuals. The registry provides, to our knowledge, the largest comparison of sex outcomes using PFA, and one of the largest using any ablation modality. The main findings are as follows: (1) there was no significant difference in the primary effectiveness outcome of 1-year recurrence of atrial arrhythmia between male and female patients (79.0% vs 76.3%; $P = .28$), (2) repeated ablation rates (male: 8.3% vs female: 10.0%; $P = .32$) were similar between sexes, (3) among the patients who underwent repeated ablation, PVI durability was higher in female than in male patients (per vein, 82.6% vs 68.1%; $P = .15$ and per patient, 63.0% vs 37.8%; $P = .005$), and (4) procedure-associated adverse events were low and did not differ significantly by sex (female: 2.5% vs male: 1.5%; $P = .19$).

Clinical Effectiveness

MANIFEST-PF demonstrated similar clinical effectiveness with PFA in both male and female individuals for both paroxysmal and persistent AF. The primary effectiveness outcome of freedom from atrial arrhythmia recurrence (>30 seconds after blanking) was 79.0% in male patients and 76.3% in female patients at 12 months of follow-up, with greater overall effectiveness in the paroxysmal AF cohort (male: 82.5% vs female: 80.2%; $P = .30$) than in the persistent AF/long-standing persistent AF cohort (male: 73.3% vs female: 67.3%; $P = .40$). These effectiveness rates compare favorably with early clinical experience with PFA.[31,32,34,36] However, none of the previous studies examining PFA for AF reported clinical outcomes according to sex.

Figure. Kaplan-Meier (KM) Analysis of Freedom From Atrial Arrhythmia by Sex



The primary effectiveness outcomes are shown for both the full patient cohort (A) and separated by atrial fibrillation (AF) subtype: paroxysmal AF (B) vs persistent AF/long-standing (LS)–persistent AF (C).

Previous studies using conventional thermal ablation technologies such as radiofrequency or cryoablation showed mixed results in ablation effectiveness between male and female individuals.[1,3,8,12,13] An analysis from the 750-patient Cryoballoon or Radiofrequency Ablation for Paroxysmal Atrial Fibrillation (FIRE AND ICE) trial, using both radiofrequency or

Table 4. Major and Minor Adverse Events

Safety outcomes	No. (%)			P value
	Entire cohort (N = 1568)	Female patients (n = 553)	Male patients (n = 1015)	
Acute major adverse events	30 (1.9)	14 (2.5)	16 (1.5)	.19
Esophageal fistula	0	0	0	NA
Symptomatic PV stenosis	0	0	0	NA
Cardiac tamponade	18 (1.1)	8 (1.4)	10 (1.0)	.46
Percutaneous drainage	14 (0.8)	5 (1.2)	9 (1.1)	>.99
Surgical drainage	2 (0.1)	2 (0.5)	0	.11
Stroke	6 (0.4)	2 (0.4)	4 (0.4)	>.99
Coronary spasm	2 (0.1)	1 (0.2)	1 (0.2)	>.99
Phrenic nerve injury (persistent)	1 (0.06)	1 (0.2)	0	NA
Death	1 (0.06)	1 (0.2)	0	.35
Vascular complications requiring surgery	2 (0.1)	1 (0.2)	1 (0.2)	>.99
Acute minor adverse events	63 (4.0)	17 (3.1)	46 (4.5)	.17
Pericardial effusion without intervention	4 (0.3)	2 (0.5)	2 (0.5)	.61
Pericarditis	1 (0.06)	0	1 (0.1)	>.99
Air embolism	4 (0.3)	2 (0.4)	2 (0.4)	.61
TIA	2 (0.1)	1 (0.2)	1 (0.2)	>.99
Phrenic nerve injury, transient	6 (0.4)	1 (0.2)	5 (0.5)	.67
Vascular access complications	41 (2.6)	10 (1.8)	31 (3.1)	.18
Hematoma	33 (2.1)	6 (1.1)	27 (2.7)	.04
A-V fistula	5 (0.3)	2 (0.4)	3 (0.3)	>.99
Pseudoaneurysm	2 (0.1)	1 (0.2)	1 (0.1)	>.99
DVT	1 (0.06)	0	1 (0.1)	>.99
Respiratory related	4 (0.3)	1 (0.2)	3 (0.3)	>.99
Chronic major adverse events	0	0	0	NA

Abbreviations: A-V, arteriovenous; DVT, deep vein thrombosis; NA, not applicable; PV, pulmonary vein; TIA, transient ischemic attack.

cryoablation, showed that female sex was associated with a 37% increase in risk of AF recurrence compared with male sex.[3] In the Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation (CABANA) trial subanalysis of 1108 patients undergoing radiofrequency ablation, 12-month AF recurrence was significantly reduced in patients undergoing ablation compared with those receiving drug therapy regardless of sex, but the effect was greater in male patients (HR, 0.48; 95% CI, 0.40-0.58) compared with female patients (HR, 0.64; 95% CI, 0.51-0.82; $P = .06$).[1] On the other hand, the Cryoballoon or Radiofrequency Ablation for Atrial Fibrillation Assessed by Continuous Monitoring (CIRCA-DOSE) substudy including 346 patients showed no significant difference in freedom from symptomatic atrial tachyarrhythmia at 1 year between male and female patients (79.1% vs 77.6%; $P = .92$).[13] Another recent single-center study including 1412 patients (radiofrequency ablation, 1349; cryoablation, 219) showed no increased risk of AF recurrence in female patients compared with male patients in both the full (HR, 1.15; 95% CI, 0.92-1.43; $P > .05$) and propensity-matched (HR, 1.08; 95% CI, 0.86-1.36; $P = .5$) cohorts.[38]

The exact mechanism(s) underlying any potential sex differences remain unclear. Putative explanations include a greater prevalence of non-PV triggers,[14,39] more advanced atrial disease, including low left atrial voltage, slower conduction and greater fractionated signals,[40] greater epicardial adipose tissue,[41] and a smaller decrease in parasympathetic activity after AF ablation[42] in female individuals. In addition, female individuals are prone to a series of inflammatory processes, including myofibroblast activation, oxidative stress, and cellular calcium overload, which are associated with atrial remodeling and AF progression.[43] Although information about AF triggers was not reported in MANIFEST-PF, there was no significant difference in the proportion of female patients compared with male patients who received additional non-PV ablation (22.4% vs 23.1%; $P = .79$); however, these lesions largely targeted substrate as opposed to triggers. The value of additional non-PV ablation for either paroxysmal or persistent AF remains uncertain, but it is certainly possible that female individuals may have more recurrences if specific triggers are not ablated.

However, among the subset of patients who underwent clinical repeated procedures, female patients had higher rates of PVI durability (per PV: 82.6% vs 68.1%; $P = .15$ and per patient: 63.0% vs 37.8%; $P = .005$). These findings of higher PVI durability in female patients compared with male patients have been previously described with radiofrequency ablation as well.[44] The reason for this difference in durability is unknown but possibly related to anatomic issues such as the left atrial size being somewhat smaller in female individuals. Of course, it is important to recognize that the group of patients requiring a repeated ablation procedure constituted only a small subset of the full cohort of 1568 patients (147 patients;

9.4%) and may not be fully representative of the full cohort. Thus, it is difficult to conclude that there was a hidden difference in sex outcomes that was offset by differential PVI durability rates.

Safety

In the MANIFEST-PF registry, the rate of major procedure-associated adverse events was low and consistent with other contemporary AF ablation studies using PFA[30,34,36] and did not differ significantly between the sex groups (female: 2.5% vs male: 1.5%). Major adverse events mostly consisted of cardiac tamponade (female: 1.4% vs male: 1.0%; $P = .46$) and stroke (0.4% vs 0.4%, $P > .99$). Importantly, there were no atrioesophageal fistulas or symptomatic PV stenosis in either sex. This is consistent with prior preclinical, first in-man clinical studies and real-world experience from the MANIFEST-PF registry, demonstrating the preferentiality of myocardial tissue susceptibility to PFA.[22,25,29-32,37]

Previous studies reporting the association of sex with AF ablation have been mixed with some studies reporting a higher risk of procedure-associated complications including cardiac tamponade, stroke/TIA, vascular complications, and major bleeding in female patients compared with male patients.[2-4,8,10,11,14] Potential explanations include the following: (1) smaller cardiac and venous structures in female individuals, making it difficult for venous access and catheter manipulation, (2) older age and greater comorbidity burden in female individuals undergoing AF ablation, (3) higher incidence of atrial fibrosis and non-pulmonary vein AF in female individuals requiring aggressive additional ablation, and (4) sex differences in genetic, hormonal, and thromboembolic factors.

The absence of sex differences for major adverse events in the MANIFEST-PF registry suggests the evolving safety of AF ablation procedures with improved transseptal puncture techniques, use of intracardiac echocardiography, advanced single-shot PFA technology that minimizes extensive catheter manipulation in the left atrium, and use of non-vitamin K oral anticoagulants.

Strengths and Limitations

This study's main strength is that MANIFEST-PF was a retrospective, nonrandomized comparative study, which, to our knowledge, was the largest PFA study to date and included multicenter patient-level data.

However, this study also has limitations. Despite extensive propensity-matched analysis and adjustment for multiple comorbidities, we cannot rule out the possibility that treatment selection and unmeasured confounders between sexes could affect the validity of the study findings. In addition, the median number of follow-up 24-hour Holter monitors used for AF monitoring was 2 (IQR, 1-3) and may have resulted in inaccurate estimates of AF recurrence rates and clinical effectiveness.

Conclusions

In this large, patient-level, observational registry of the first postapproval clinical use of PFA to treat AF, results suggest that there were no sex differences in clinical effectiveness or safety. The current data sets the stage for further studies using systematic, longer-term monitoring methods to confirm the effectiveness of PFA in male and female individuals.

ARTICLE INFORMATION

Accepted for Publication: August 10, 2023.

Published Online: November 1, 2023. doi:10.1001/jamacardio.2023.3752

Author Affiliations: Helmsley Electrophysiology Center, Icahn School of Medicine at Mount Sinai, New York, New York (Turagam, Reddy); Cardiology Department, Na Homolce Hospital, Homolka Hospital, Prague, Czechia (Neuzil, Funasako, Petru, Reddy); Medizinisches Versorgungszentrum Cardioangiologisches Centrum Bethanien Frankfurt und Main-Taunus GbR, Frankfurt, Germany (Schmidt, Chun); Inselspital—Bern University Hospital, University of Bern, Bern, Switzerland (Reichlin, Roten, Kueffer); Department of Medicine, Witten/Herdecke University, Witten, Germany (Neven, Füting); Department of Electrophysiology, Alfried Krupp Hospital, Essen, Germany (Neven, Füting); University Heart & Vascular Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (Metzner, Lemoine); Department of Cardiology, Herlev-Gentofte University Hospital, Hellerup, Denmark (Hansen, Ruwald); Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands (Blaauw, Mulder); Department of Cardiology, University Hospital Rangueil, Toulouse, France (Maury, Rollin); I2MC Institute, INSERM UMR 1297, Toulouse, France (Maury); Department of Cardiology and Angiology, Medical Center and Faculty of Medicine—University of Freiburg, Germany (Arentz, Lehrmann); Clinic for Electrophysiology, Herz- und Diabeteszentrum North Rhine Westfalia, Ruhr-University Bochum, Bad Oeynhausen, Germany (Sommer, Fink); Department for Cardiovascular Diseases, University Hospital Center Split, Split, Croatia (Anic, Jurisic); Department of Cardiology, Rouen Hospital, Rouen, France (Anselme, Chaumont); Heart Rhythm Department, Clinique Pasteur, Toulouse, France (Boveda, Adelino); Universitair Ziekenhuis, Brussels, Belgium (Boveda, Adelino); Heart Center Bad Neustadt, Rhoen-Clinic Campus Bad Neustadt, Bad Neustadt an der Saale, Germany (Deneke, Nentwich); Asklepios Hospital St Georg, Hamburg, Germany (Willems, Gunawardene); Catharina Hospital, Eindhoven, the Netherlands instead of Catharina Ziekenhuis Eindhoven, the Netherlands (van der Voort, Ouss); University Heart Center Lübeck, Department of Rhythmology, University Hospital Schleswig-Holstein, Germany (Tilz, Heeger); German Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Lübeck, Lübeck, Germany (Tilz, Heeger); Neuron Medical, Brno, Czech Republic (Funasako); Division of Cardiology, Department of Internal Medicine, Medical University of Graz, Graz, Austria (Scherr, Manninger); Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center Essen, University Duisburg-Essen, Duisburg, Germany (Wakili, Bohnen); Heart Center University Hospital of Cologne, Department for Electrophysiology, Cologne, Germany (Steven, Sultan); IKEM—Institute for Clinical and Experimental Medicine, Prague, Czech Republic (Kautzner, Peichl); Department of Cardiology, Jessa Hospitals, Hasselt, Belgium (Vijgen, Koopman); IHU LIRYC—Institute Des Maladies Du Rythme Cardiaque, CHU Bordeaux, University of Bordeaux, Bordeaux, France (Jais, Derval).

Author Contributions: Drs Turagam and Reddy had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Turagam, Reichlin, Arentz, Sommer, Steven, Reddy.
Acquisition, analysis, or interpretation of data: Neuzil, Schmidt, Reichlin, Neven, Metzner, Hansen, Blaauw, Maury, Arentz, Anic, Anselme, Boveda, Deneke, Willems, van der Voort, Tilz, Funasako, Scherr, Wakili, Steven, Kautzner, Vijgen, Jais, Petru, Chun, Roten, Füting, Lemoine, Ruwald, Mulder, Rollin, Lehrmann, Fink, Jurišić, Chaumont, Adeliño, Nentwich, Gunawardene, Ouss, Heeger, Manninger, Bohnen, Sultan, Peichl, Koopman, Derval, Kueffer, Reddy.
Drafting of the manuscript: Turagam, Willems, Scherr, Rollin, Reddy.
Critical review of the manuscript for important intellectual content: Neuzil, Schmidt, Reichlin, Neven, Metzner, Hansen, Blaauw, Maury, Arentz,

Sommer, Anic, Anselme, Boveda, Deneke, Willems, van der Voort, Tilz, Funasako, Scherr, Wakili, Steven, Kautzner, Vijgen, Jais, Petru, Chun, Roten, Füting, Lemoine, Ruwald, Mulder, Lehrmann, Fink, Jurišić, Chaumont, Adeliño, Nentwich, Gunawardene, Ouss, Heeger, Manninger, Bohnen, Sultan, Peichl, Koopman, Derval, Kueffer, Reddy.
Statistical analysis: Turagam, Fink.
Obtained funding: Reichlin, Jais.
Administrative, technical, or material support: Neven, Hansen, Blaauw, Arentz, Sommer, Anic, Boveda, Deneke, Willems, van der Voort, Scherr, Petru, Chun, Füting, Jurišić, Adeliño, Heeger, Bohnen, Kueffer, Reddy.
Supervision: Neuzil, Schmidt, Reichlin, Hansen, Anic, Steven, Vijgen, Jais, Mulder, Lehrmann, Sultan, Reddy.

Conflict of Interest Disclosures: Dr Schmidt reported receiving grants from Boston Scientific, Medtronic, Biosense Webster, and Abbott outside the submitted work. Dr Reichlin reported receiving grants from Boston Scientific/Farapulse, the Swiss National Science Foundation, the Swiss Heart Foundation, the Swiss Institute for Translational and Entrepreneurial Medicine (sitem insel) support fund, Biotronik, and Medtronic and speaker/consulting honoraria or travel support from Abbott/SJM, Biosense Webster, Biotronik, Boston Scientific, and Medtronic outside the submitted work. Dr Neven reported receiving personal fees from Biosense Webster and Boston Scientific outside the submitted work. Dr Metzner reported receiving personal fees from Boston Scientific, Medtronic, and Biosense Webster outside the submitted work. Dr Hansen reported receiving personal fees from Boston Scientific and Biosense Webster/J&J outside the submitted work. Dr Sommer reported receiving grants from Boston Scientific during the conduct of the study. Dr Anic reported receiving consulting fees from Boston Scientific and Galvanize Therapeutics outside the submitted work. Dr Anselme reported receiving personal fees from Boston Scientific, Medtronic, and Microport CRM, and grants from Medtronic and Boston Scientific outside the submitted work. Dr Boveda reported receiving consultant fees from Boston Scientific, Medtronic, Microport, and Zoll outside the submitted work. Dr Deneke reported receiving speaker fees from Biotronik, Abbott, and Biosense Webster. Dr Willems reported speaker fees from Boston Scientific, Abbott, and Bristol Myers Squibb and grants from Boston Scientific and grants from Abbott outside the submitted work. Dr Tilz reported receiving consultant fees from Boston Scientific, Biotronik, Biosense Webster, and Abbott Medical; speaker honoraria from Boston Scientific, Biotronik, Biosense Webster, Abbott Medical, and Lifetech; and research grants from Abbott, Biosense Webster, and Lifetech outside the submitted work. Dr Wakili reported receiving speaker honoraria from Boston Scientific, Medtronic, Daiichi Sankyo, Bayer, Boehringer Ingelheim, Biotronik, Pfizer, and BMS; advisory board fees from Boston Scientific, Medtronic, Daiichi Sankyo, and Boehringer Ingelheim; participating in clinical trials for Boston Scientific, Boehringer Ingelheim, and Daiichi Sankyo; and receiving research funding from BMS/Pfizer and Boston Scientific. Dr Kautzner reported receiving advisory board fees from Boston Scientific, Biosense Webster, Medtronic, and Abbott outside the submitted work. Dr Jais reported receiving grants from Boston Scientific during the conduct of the study. Dr Roten reported receiving grants from Medtronic, consulting fees from Medtronic, and speaker fees from Abbott outside the submitted work. Dr Lemoine reported receiving grants from Farapulse outside the submitted work. Dr Chaumont reported receiving consultant/speaker fees from Medtronic outside the submitted work. Dr Gunawardene reported receiving personal fees from Farapulse/Boston Scientific, Abbott Medical, Medtronic, and Emmes and travel fees from Biosense Webster outside the submitted work. Dr Heeger reported receiving personal fees from Boston Scientific during the conduct of the study. Dr Manninger reported receiving grants from Bayer Healthcare, Biosense Webster, Biotronik, AOP Orphan, Boston Scientific, Daichii Sankyo, BMS/Pfizer, and Abbott outside the submitted work. Dr Sultan reported receiving personal fees from Boston Scientific, Abbott, Medtronic, and J&J outside the submitted work. Dr Peichl reported receiving personal fees from Boston Scientific outside the submitted work. Dr Koopman reported receiving grants from Medtronic, Boston Scientific, Biotronik, Abbott, Pfizer, Daiichi Sankyo, and Bayer and personal fees from Cardiofocus, Bayer, and Boston Scientific outside the submitted work. Dr Reddy reported receiving grants from Farapulse-Boston Scientific; serving as a consultant for and having equity in Ablacon, Acutus Medical, Affera-Medtronic, Apama Medical–Boston Scientific, Anumana, APN Health, Aquaheart, Atacor, Autonomix, Axon Therapies, Backbeat, BioSig, CardiaCare, CardioNXT/AFTx, Circa Scientific, CoRISMA, Corvia Medical, Dinova-Hangzhou DiNovA EP Technology, East End Medical, EPD-Philips, EP Frontiers, Epix Therapeutics-Medtronic, EpiEP, Eximo, Field Medical, Focused Therapeutics, HRT, Intershunt, Javelin, Kardium, Keystone Heart, LuxMed, Medlumics, Middlepeak, Neutrace, Nuvera-Biosense Webster, Oracle Health, Restore Medical, Sirona Medical, SoundCath, and Valcare; serving as a consultant for AtriAN, Biosense-Webster, BioTel Heart, Biotronik, Cairdac, Cardiofocus, Cardionomic, CoreMap, Fire1, Gore & Associates, Impulse Dynamics, Medtronic, Novartis, Philips, and Pulse Biosciences; and having equity in Manual Surgical Sciences, Newpace, Nyra Medical, Surecor, and Vizaramed outside the submitted work. No other disclosures were reported.

Funding/Support: This work was supported by Boston Scientific.

Role of the Funder/Sponsor: The funder provided a grant to support data collection but was not otherwise involved with the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Data Sharing Statement: See Supplement 2.

Additional Contributions: We thank Nico Reinsch, MD, affiliated with Alfried Krupp Krankenhaus Ruttenscheid, for helping facilitate the data collection. No financial compensation was received for this contribution.

REFERENCES

1. Russo AM, Zeitler EP, Giczewska A, et al; CABANA Investigators. association between sex and treatment outcomes of atrial fibrillation ablation vs drug therapy: results from the CABANA trial. *Circulation*. 2021;143(7):661-672. doi:10.1161/CIRCULATIONAHA.120.051558

2. Cheung JW, Cheng EP, Wu X, et al. Sex-based differences in outcomes, 30-day readmissions, and costs following catheter ablation of atrial fibrillation: the US Nationwide Readmissions Database 2010-14. *Eur Heart J*. 2019;40(36):3035-3043. doi:10.1093/eurheartj/ehz151

3. Kuck KH, Brugada J, Fürnkranz A, et al; FIRE AND ICE Investigators. Impact of female sex on clinical outcomes in the FIRE AND ICE trial of catheter ablation for atrial fibrillation. *Circ Arrhythm Electrophysiol*. 2018;11(5):e006204. doi:10.1161/CIRCEP.118.006204

4. Kaiser DW, Fan J, Schmitt S, et al. Gender differences in clinical outcomes after catheter ablation of atrial fibrillation. *JACC Clin Electrophysiol*. 2016;2(6):703-710. doi:10.1016/j.jacep.2016.04.014

5. Elayi CS, Darrat Y, Suffredini JM, et al. Sex differences in complications of catheter ablation for atrial fibrillation: results on 85 977 patients. *J Interv Card Electrophysiol*. 2018;53(3):333-339. doi:10.1007/s10840-018-0416-1

6. Asad ZUA, Yousif A, Khan MS, Al-Khatib SM, Stavrakis S. Catheter ablation vs medical therapy for atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials. *Circ Arrhythm Electrophysiol*. 2019;12(9):e007414. doi:10.1161/CIRCEP.119.007414

7. Winkle RA, Jarman JW, Mead RH, et al. Predicting atrial fibrillation ablation outcome: the CAAP-AF score. *Heart Rhythm*. 2016;13(11):2119-2125. doi:10.1016/j.hrthm.2016.07.018

8. Cheng X, Hu Q, Gao L, Liu J, Qin S, Zhang D. Sex-related differences in catheter ablation of atrial fibrillation: a systematic review and meta-analysis. *Europace*. 2019;21(10):1509-1518. doi:10.1093/europace/euz179

9. Ngo L, Ali A, Ganesan A, Woodman R, Adams R, Ranasinghe I. Gender differences in complications following catheter ablation of atrial fibrillation. *Eur Heart J Qual Care Clin Outcomes*. 2021;7(5):458-467. doi:10.1093/ehjqcco/qcab035

10. Zylla MM, Brachmann J, Lewalter T, et al. Sex-related outcome of atrial fibrillation ablation: insights from the German Ablation Registry. *Heart Rhythm*. 2016;13(9):1837-1844. doi:10.1016/j.hrthm.2016.06.005

11. Michowitz Y, Rahkovich M, Oral H, et al. Effects of sex on the incidence of cardiac tamponade after catheter ablation of atrial fibrillation: results from a worldwide survey in 34 943 atrial fibrillation ablation procedures. *Circ Arrhythm Electrophysiol*. 2014;7(2):274-280. doi:10.1161/CIRCEP.113.000760

12. Li H, Wang Z, Cheng Z, et al. Sex differences involved in persistent atrial fibrillation recurrence after radiofrequency ablation. *BMC Cardiovasc Disord*. 2022;22(1):549. doi:10.1186/s12872-022-03002-z

13. Yao RJR, Macle L, Deyell MW, et al; CIRCA-DOSE Study Investigators. Impact of female sex on clinical presentation and ablation outcomes in the CIRCA-DOSE study. *JACC Clin Electrophysiol*. 2020;6(8):945-954. doi:10.1016/j.jacep.2020.04.032

14. Patel D, Mohanty P, Di Biase L, et al. Outcomes and complications of catheter ablation for atrial fibrillation in females. *Heart Rhythm*. 2010;7(2):167-172. doi:10.1016/j.hrthm.2009.10.025

15. Akoum N, Mahnkopf C, Kholmovski EG, Brachmann J, Marrouche NF. Age and sex differences in atrial fibrosis among patients with atrial fibrillation. *Europace*. 2018;20(7):1086-1092. doi:10.1093/europace/eux260

16. Forleo GB, Tondo C, De Luca L, et al. Gender-related differences in catheter ablation of atrial fibrillation. *Europace*. 2007;9(8):613-620. doi:10.1093/europace/eum144

17. van Driel VJ, Neven KG, van Wessel H, et al. Pulmonary vein stenosis after catheter ablation: electroporation vs radiofrequency. *Circ Arrhythm Electrophysiol*. 2014;7(4):734-738. doi:10.1161/CIRCEP.113.001111

18. van Driel VJ, Neven K, van Wessel H, Vink A, Doevendans PA, Wittkampf FH. Low vulnerability of the right phrenic nerve to electroporation ablation. *Heart Rhythm*. 2015;12(8):1838-1844. doi:10.1016/j.hrthm.2015.05.012

19. Neven K, van Es R, van Driel V, et al. Acute and long-term effects of full-power electroporation ablation directly on the porcine esophagus. *Circ Arrhythm Electrophysiol*. 2017;10(5):e004672. doi:10.1161/CIRCEP.116.004672

20. Koruth J, Kuroki K, Iwasawa J, et al. Preclinical evaluation of pulsed field ablation: electrophysiological and histological assessment of thoracic vein isolation. *Circ Arrhythm Electrophysiol*. 2019;12(12):e007781. doi:10.1161/CIRCEP.119.007781

21. Stewart MT, Haines DE, Verma A, et al. Intracardiac pulsed field ablation: proof of feasibility in a chronic porcine model. *Heart Rhythm*. 2019;16(5):754-764. doi:10.1016/j.hrthm.2018.10.030

22. Koruth JS, Kuroki K, Kawamura I, et al. Pulsed field ablation versus radiofrequency ablation: esophageal injury in a novel porcine model. *Circ Arrhythm Electrophysiol*. 2020;13(3):e008303. doi:10.1161/CIRCEP.119.008303

23. Koruth JS, Kuroki K, Kawamura I, et al. Focal pulsed field ablation for pulmonary vein isolation and linear atrial lesions: a preclinical assessment of safety and durability. *Circ Arrhythm Electrophysiol*. 2020;13(6):e008716. doi:10.1161/CIRCEP.120.008716

24. Yavin H, Shapira-Daniels A, Barkagan M, et al. Pulsed field ablation using a lattice electrode for focal energy delivery: biophysical characterization, lesion durability, and safety evaluation. *Circ Arrhythm Electrophysiol*. 2020;13(6):e008580. doi:10.1161/CIRCEP.120.008580

25. Howard B, Haines DE, Verma A, et al. Reduction in pulmonary vein stenosis and collateral damage with pulsed field ablation compared with radiofrequency ablation in a canine model. *Circ Arrhythm Electrophysiol*. 2020;13(9):e008337. doi:10.1161/CIRCEP.120.008337

26. Howard B, Haines DE, Verma A, et al. Characterization of phrenic nerve response to pulsed field ablation. *Circ Arrhythm Electrophysiol*. 2022;15(6):e010127. doi:10.1161/CIRCEP.121.010127

27. Kotnik T, Rems L, Tarek M, Miklavčič D. Membrane electroporation and electropermeabilization: mechanisms and models. *Annu Rev Biophys*. 2019;48:63-91. doi:10.1146/annurev-biophys-052118-115451

28. Koruth J, Verma A, Kawamura I, et al. PV isolation using a spherical array PFA catheter: preclinical assessment and comparison to radiofrequency ablation. *JACC Clin Electrophysiol*. 2023;9(5):652-666. doi:10.1016/j.jacep.2023.01.022

29. Reddy VY, Koruth J, Jais P, et al. Ablation of atrial fibrillation with pulsed electric fields: an ultrarapid, tissue-selective modality for cardiac ablation. *JACC Clin Electrophysiol*. 2018;4(8):987-995. doi:10.1016/j.jacep.2018.04.005

30. Reddy VY, Neuzil P, Koruth JS, et al. Pulsed field ablation for pulmonary vein isolation in atrial fibrillation. *J Am Coll Cardiol*. 2019;74(3):315-326. doi:10.1016/j.jacc.2019.04.021

31. Reddy VY, Dukkipati SR, Neuzil P, et al. Pulsed field ablation of paroxysmal atrial fibrillation: 1-year outcomes of IMPULSE, PEFCAT, and PEFCAT II. *JACC Clin Electrophysiol*. 2021;7(5):614-627. doi:10.1016/j.jacep.2021.02.014

32. Reddy VY, Anic A, Koruth J, et al. Pulsed field ablation in patients with persistent atrial fibrillation. *J Am Coll Cardiol*. 2020;76(9):1068-1080. doi:10.1016/j.jacc.2020.07.007

33. Ekanem E, Reddy VY, Schmidt B, et al; MANIFEST-PF Cooperative. Multinational survey on the methods, efficacy, and safety on the post-approval clinical use of pulsed field ablation (MANIFEST-PF). *Europace*. 2022;24(8):1256-1266. doi:10.1093/europace/euac050

34. Verma A, Haines DE, Boersma LV, et al; PULSED AF Investigators. Pulsed field ablation for the treatment of atrial fibrillation: PULSED AF pivotal trial. *Circulation*. 2023;147(19):1422-1432. doi:10.1161/CIRCULATIONAHA.123.063988

35. Reddy VY, Neuzil P, Anic A. Reply: pulsed field ablation for persistent atrial fibrillation: do electrophysiological endpoints predict clinical benefit? *J Am Coll Cardiol*. 2020;76(25):3065-3066. doi:10.1016/j.jacc.2020.10.044

36. Duytschaever M, De Potter T, Grimaldi M, et al; inspIRE Trial Investigators. Paroxysmal AF ablation using a novel variable-loop biphasic pulsed field ablation catheter integrated with a 3D mapping system: 1-year outcomes of the multicenter inspIRE study. *Circ Arrhythm Electrophysiol*. 2023;16(3):e011780. doi:10.1161/CIRCEP.122.011780

37. Turagam MK, Neuzil P, Schmidt B, et al. Safety and effectiveness of pulsed field ablation to treat atrial fibrillation: 1-year outcomes from the MANIFEST-PF registry. *Circulation*. 2023;148(1):35-46. doi:10.1161/CIRCULATIONAHA.123.064959

38. Al-Sadawi M, Aslam F, Gier C, et al. Effect of gender on atrial fibrillation ablation outcomes using a propensity score-matched analysis. *Heart Rhythm O2*. 2023;4(5):309-316. doi:10.1016/j.hroo.2023.01.006

39. Takigawa M, Takahashi A, Kuwahara T, et al. Long-term outcome after catheter ablation of paroxysmal atrial fibrillation: impact of different atrial fibrillation foci. *Int J Cardiol*. 2017;227:407-412. doi:10.1016/j.ijcard.2016.11.028

40. Wong GR, Nalliah CJ, Lee G, et al. Sex-related differences in atrial remodeling in patients with atrial fibrillation: relationship to ablation outcomes. *Circ Arrhythm Electrophysiol*. 2022;15(1):e009925. doi:10.1161/CIRCEP.121.009925

41. Kim JS, Shin SY, Kang JH, et al. Influence of sex on the association between epicardial adipose tissue and left atrial transport function in patients with atrial fibrillation: a multislice computed tomography study. *J Am Heart Assoc*. 2017;6(8):e006077. doi:10.1161/JAHA.117.006077

42. Yu HT, Yang PS, Kim TH, et al. Poor rhythm outcome of catheter ablation for early-onset atrial fibrillation in women—mechanistic insight. *Circ J*. 2018;82(9):2259-2268. doi:10.1253/circj.CJ-17-1358

43. Jalife J, Kaur K. Atrial remodeling, fibrosis, and atrial fibrillation. *Trends Cardiovasc Med*. 2015;25(6):475-484. doi:10.1016/j.tcm.2014.12.015

44. Sugumar H, Nanayakkara S, Chieng D, et al. Arrhythmia recurrence is more common in females undergoing multiple catheter ablation procedures for persistent atrial fibrillation: time to close the gender gap. *Heart Rhythm*. 2020;17(5 Pt A):692-698. doi:10.1016/j.hrthm.2019.12.013

Invited Commentary

Pulsed Field Closes Gender Gap in Atrial Fibrillation Ablation—Electrifying Insights

Peter M. Kistler, MBBS, PhD; Louise Segan, MBBS, MPH

Pulmonary vein isolation (PVI) is the cornerstone of atrial fibrillation (AF) ablation. Innovations in catheter-ablation technologies and procedural techniques have enhanced PVI durability, with success rates approaching 80% in contemporary randomized studies.[1] Although catheter ablation is the most effective rhythm-control strategy for AF, it is associated with a significant learning curve and is not without the risk of complications.[2] The recent emergence of pulsed field ablation (PFA) as a novel nonthermal technology has been met with great enthusiasm with early reports of high rates of durable single-procedure PVI. Additionally, procedure times and training requirements appear shorter with enhanced safety due to myocardial tissue selectivity, reducing the risk of collateral damage to surrounding structures.[3] However, it is not known whether there is gender equity in these perceived advantages. Women are typically underrecognized in clinical AF trials. This sex disparity is important to address as there have been mixed reports on the impact of sex on the success and safety of AF ablation.[4-7]

Related article page 1142

In this issue of *JAMA Cardiology*, Turagam et al[8] present a retrospective sex-stratified analysis of the Multi-National Sur-